Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study

被引：0
|
作者：
Richardson, P. G.
Chanan-Khan, A.
Lonial, S.
Krishnan, A.
Carroll, M.
Alsina, M.
Albitar, M.
Berman, D.
Kaplita, S.
Anderson, K.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[3] Emory Univ, Sch Med, Atlanta, GA 30322 USA
[4] City Hope Comprehens Canc Ctr, Duarte, CA USA
[5] Sutter Reg Canc Inst, Sacramento, CA USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[7] Nichols Inst, San Juan Capistrano, CA USA
[8] Bristol Myers Squibb Co, Princeton, NJ USA
[9] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8503
引用
收藏
页数：2
相关论文
共 50 条
  • [1] TANESPIMYCIN AND BORTEZOMIB IN PATIENTS WITH RELAPSED AND RELAPSED AND REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE 1/2 STUDY
    Richardson, P. G.
    Chanan-Khan, A.
    Lonial, S.
    Krishnan, A.
    Carroll, M.
    Alsina, M.
    Albitar, M.
    Berman, D.
    Szatrowski, T.
    Kaplita, S.
    Anderson, K. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 152 - 153
  • [2] Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial
    Richardson, Paul G.
    Wolf, Jeffrey Lee
    Jakubowiak, Andrzej J.
    Zonder, Jeffrey A.
    Lonial, Sagar
    Irwin, David
    Densmore, John
    Krishnan, Amrita
    Raje, Noopur S.
    Bar, Michael H.
    Schlossman, Robert
    Ghobrial, Irene M.
    Munshi, Nikhil C.
    Martin, Thomas
    Laubach, Jacob P.
    Allerton, Jeffrey P.
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Anderson, Kenneth C.
    BLOOD, 2011, 118 (21) : 371 - 371
  • [3] Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
    Richardson, Paul G.
    Chanan-Khan, Asher A.
    Lonial, Sagar
    Krishnan, Amrita Y.
    Carroll, Michael P.
    Alsina, Melissa
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (06) : 729 - 740
  • [4] Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma
    Richardson, Paul G.
    Badros, Ashraf Z.
    Jagannath, Sundar
    Tarantolo, Stefano
    Wolf, Jeffrey L.
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (04) : 428 - 437
  • [5] Tanespimycin plus Bortezomib in Relapsed/Refractory Myeloma Patients: Results From the Time-2 Study
    Badros, Ashraf Z.
    Richardson, Paul G.
    Albitar, Maher
    Jagannath, Sundar
    Tarantolo, Stefano
    Wolf, Jeffrey L.
    Messina, Marianne
    Berman, David
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (22) : 742 - 743
  • [6] ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study
    Ocio, Enrique M.
    Efebera, Yvonne A.
    Hajek, Roman
    Straub, Jan
    Maisnar, Vladimir
    Eveillard, Jean-Richard
    Karlin, Lionel
    Mateos, Maria -Victoria
    Oriol, Albert
    Ribrag, Vincent
    Richardson, Paul G.
    Norin, Stefan
    Obermueller, Jakob
    Bakker, Nicolaas A.
    Pour, Ludek
    HAEMATOLOGICA, 2024, 109 (03) : 867 - 876
  • [7] Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib
    Ghobrial, Irene M.
    Weller, Edie
    Vij, Ravi
    Munshi, Nikhil C.
    Banwait, Ranjit
    Rourke, Meghan
    Schlossman, Robert L.
    Laubach, Jacob P.
    Jakubowiak, Andrzej J.
    Leduc, Renee
    Chuma, Stacey
    Kunsman, Janet
    Dollard, Akari M.
    Warren, Diane
    Harris, Brianna
    Poon, Tiffany
    Sam, Amy
    Rodig, Scott J.
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2010, 116 (21) : 435 - 436
  • [8] Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
    Richardson, Paul G.
    Wolf, Jeff
    Jakubowiak, Andrzej
    Zonder, Jeff
    Lonial, Sagar
    Irwin, David
    Densmore, John
    Krishnan, Amrita
    Raje, Noopur
    Bar, Michael
    Martin, Tom
    Schlossman, Robert
    Ghobrial, Irene M.
    Munshi, Nikhil
    Laubach, Jacob
    Allerton, Jeff
    Hideshima, Teru
    Colson, Kathleen
    Poradosu, Enrique
    Gardner, Lesa
    Sportelli, Peter
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4243 - 4249
  • [9] Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Shain, Kenneth H.
    Laubach, Jacob
    Henrick, Patrick
    Vredenburg, James
    Crilley, Pamela
    Constantine, Michael
    Block, Caroline
    Basile, Frank G.
    Cappuccio, Joseph
    Azab, Abdel Kareem
    Lai, Emily
    Caola, Aaron
    Banwait, Ranjit
    Savell, Alexandra
    Munshi, Nikhil C.
    Paba-Prada, Claudia E.
    Schlossman, Robert L.
    Chuma, Stacey
    Noonan, Kimberly
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2015, 126 (23)
  • [10] A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma
    Ghobrial, Irene M.
    Munshi, Nikhil C.
    Harris, Brianna N.
    Shi, Peipei
    Porter, Nichole M.
    Schlossman, Robert L.
    Laubach, Jacob P.
    Anderson, Kenneth C.
    Desaiah, Durisala
    Myrand, Scott P.
    Wooldridge, James E.
    Richardson, Paul G.
    Abonour, Rafat
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (07) : 573 - 578
12345